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Abstract 
Modafinil is a novel wakefulness-promoting medication that has become popularised 
for purposes of cognitive enhancement. Research has indicated that modafinil may 
improve inhibitory control-related functioning, though to date no studies have 
attempted to explore these effects using electrophysiological methods. This study 
investigated the effect of 200mg of modafinil on behavioural (RT and accuracy) and 
electrophysiological (N2 amplitude) correlates of inhibitory control within a sample 
of 18 healthy, non-sleep deprived males aged 19-27 years. Participants completed 
pre- and post-ingestion versions of a Flanker Go/Nogo paradigm over two double-
blind, placebo-controlled experimental conditions. Results indicated that while 
modafinil maintained baseline levels of mood, sleepiness and alertness to a 
significantly greater extent than placebo, no effect on inhibitory control processes 
was observed on RT, accuracy, or amplitude of the N2 component. Despite this, 
tentative evidence was found for an overall improvement in processing speed 
following modafinil ingestion, independent of inhibitory control processes. Future 
research is necessary to investigate these effects further, and determine the extent to 
which they manifest independently from fatigue-inducing environments. 
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Modafinil is a novel wake-promoting agent, or eugeroic, intended for use in 
the treatment of excessive daytime sleepiness. First developed in the early 1990s and 
licensed in Australia in 2002, modafinil is presently approved by the Therapeutic 
Drug Administration as a Schedule-IV prescription treatment for narcolepsy, chronic 
shift-work sleep disorder, and obstructive sleep apnoea (TGA, 2008). Despite this, 
recognition of a low abuse liability and lack of adverse effects has led to modafinil 
being utilised for a range of off-label indications, including depression, attention-
deficit/hyperactivity disorder, multiple sclerosis, and chronic fatigue (Farah, Smith, 
Ilieva, & Hamilton, 2014; Minzenberg & Carter, 2008). Notably, modafinil use has 
emerged among healthy populations as a means of pharmaceutical 
neuroenhancement: the use of pharmaceutical substances for the targeted 
enhancement of cognitive, affective and motivational function (Repantis, 
Schlattmann, Laisney, & Heuser, 2010). Commonly recognised as a nootropic or 
‘smart drug’, modafinil is often considered in context with other popular 
pharmacological neuroenhancers, including caffeine, piracetam, methylphenidate and 
dexamphetamine.   
An informal online poll conducted by Nature has indicated that the most 
common demographic using modafinil and other cognitive enhancing agents were 
those aged from 18 to 25, with the primary purpose being to improve concentration 
or focus for specific tasks (Maher, 2008). Use among other groups has also 
popularised modafinil as a cognitive enhancer, with reports of surgeons using 
modafinil for purposes of combating fatigue and loss of concentration (Franke et al., 
2013), and US air force pilots, for whom modafinil has been approved for use on 
missions lasting longer than 12 hours (Repantis et al., 2010; USAF, 2004). The 
increasing exposure of modafinil for these purposes has consequently led to an 
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extensive body of research aimed at investigating the potential cognitive enhancing 
effects of modafinil among both sleep-deprived and well-rested populations, with 
emphasis on areas of attention, memory, learning, and executive functions. In 
particular, a number of studies have indicated that modafinil may enhance processes 
related to inhibitory control. To date, however, no studies have attempted to utilise 
temporally precise techniques such as event-related potentials (ERPs) to investigate 
effects of modafinil on this specific cognitive process. 
Neurochemical Effects and Mechanisms of Action  
Despite the increasing usage and off-label applications of modafinil, the 
mechanism by which modafinil may produce wakefulness-promoting and cognitive 
enhancing effects is yet to be conclusively identified (Qu, Huang, Xu, Matsumoto, & 
Urade, 2008). Although frequently associated with amphetamines due to its wake-
promoting properties, it is now recognised that the pharmacological profile and 
behavioural effects of modafinil are distinct from other psychostimulants, indicating 
a unique mechanism of action (Minzenberg & Carter, 2008). To date, there is strong 
evidence that the direct modulation of catecholamine transporters, specifically 
norepinephrine and dopamine in areas of the prefrontal cortex and hypothalamus, are 
primary to the wakefulness enhancing effects of modafinil (de Saint Hilaire, Orosco, 
Rouch, Blanc, & Nicolaidis, 2001; Madras et al., 2006; Qu et al., 2008). Secondary 
to catecholamine effects, extracellular reductions in GABA and elevations in 
serotonin, glutamate, orexin, and histamine systems are also observed, again with 
particular prominence in neocortical areas relative to subcortical structures 
(Minzenberg & Carter, 2008). The apparent role of catecholamine modulation at 
prefrontal sites has consequently fuelled interest regarding the effects of modafinil on 
aspects of attention and executive functions. 
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Attention, Executive Functions and Inhibitory Control 
Given that the enhancement of selective attention, concentration, and 
inhibition of distraction is a primary motivator for many people seeking both 
modafinil and other forms of cognitive enhancement (Maher, 2008), investigating the 
influence of modafinil on executive functions and particularly inhibitory control has 
become a key focus of many studies. Petersen and Posner’s (2012) model of the 
attentional system states that in addition to both the alerting and orienting networks, 
executive functions form one of the three primary systems of the attentional network. 
Executive functions encompass a set of top-down cognitive processes involved in the 
selection and manipulation of incoming information, and are commonly associated 
with higher-order functions such as planning, decision-making and adaptive 
reasoning. Diamond’s (2013) model of executive functions states that these higher-
order functions derive from the interactions of three core executive processes: 
inhibition, working memory, and cognitive flexibility. Inhibition, or inhibitory 
control, hence constitutes an integral component of the executive system, and 
primarily involves the ability to inhibit irrelevant information and focus attention or 
behaviour towards more goal-directed or appropriate action.   
Inhibitory control is itself further subdivided into facets of behavioural 
inhibition and cognitive inhibition or selective attention (Diamond, 2013). 
Behavioural inhibition, or ‘self-control’, involves the resistance of temptation or 
impulsivity to making prepotent responses. In a behavioural sense, inhibitory control 
aids in inhibiting or overcoming a dominant response, often in order to perform a 
subdominant one. In this way, behavioural inhibition allows individuals to avoid 
common errors of impulsivity and instead formulate more measured or intentional 
responses. Cognitive or attentional inhibition, by contrast, acts as a mediator of 
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attentional distribution, enabling selective attention to particular stimuli whilst 
suppressing interference from others. Also referred to as focused attention, this form 
of inhibition or attentional control enables the voluntary inhibition of certain 
environmental stimuli based on current goals or intentions of attending (Diamond, 
2013). 
Modafinil in Healthy, Sleep Deprived Individuals 
 The cognitive enhancing effects of modafinil following sleep-deprivation 
have been extensively researched, particularly given the status of modafinil as a 
wakefulness-promoting agent. Studies in this area have largely focused on more 
general effects of wakefulness and maintaining performance on ecologically valid 
tasks, such as flight simulators in military personnel (Repantis et al., 2010). 
However, enhancement of executive functions has also been investigated, primarily 
due to the negative effects that sleep deprivation may have on these processes, and 
their importance in daily functioning (Wesensten, 2006). 
 A systematic review by Repantis et al. (2010) examined the efficacy of 
modafinil for neuroenhancement across 31 studies pertaining to both sleep-deprived 
and non-sleep deprived populations. Neuroenhancement was investigated in relation 
to attention, mood, memory, wakefulness, and executive functions. In studies on 
sleep deprived individuals, they reported that single dose administration produced 
large improvements in wakefulness (d=2.6), memory (d=1.22), and executive 
functions (d=3.3), with no significant effects on attention or mood. Effects on 
executive functions were indicated to be very strong and persistent over time, though 
this was not observed for repeated administration studies involving long periods of 
sleep-deprivation, where only wakefulness was modulated by modafinil (Repantis et 
al., 2010). 
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 As an integral part of the executive system, processes of inhibitory control are 
evidently implicated in any enhancement of executive functions. In a simulated night 
shift study (n=32), 200mg of modafinil was found to significantly enhance alertness, 
vigilance, and performance on tasks of executive functions and inhibitory processes 
(Walsh, Randazzo, Stone, & Schweitzer, 2004). Participants who had been 
administered modafinil, showed significant improvements on the Maintenance of 
Wakefulness Test and Psychomotor Vigilance Test. Enhanced performance was also 
observed in the Wisconsin Card Sorting Test and Haylings Sentence Completion 
Test; two tests involving executive functions and response inhibition. Further 
evidence for enhancement inhibitory processes in sleep-deprived populations is 
evident in a study by Wesensten, Killgore and Balkin (2005), in which 400mg of 
modafinil following 85 hours of sleep deprivation countered performance 
impairments on the Stroop task, suggesting modafinil effectively maintained 
processes of selective attention and interference inhibition. 
Modafinil in Healthy, Non-Sleep Deprived Individuals 
 While Repantis et al. (2010) demonstrated effects of cognitive enhancement, 
and particularly enhancement of executive functions, following modafinil 
administration in moderately sleep-deprived individuals, they propose that the extent 
of these effects remains equivocal in well-rested populations. In studies pertaining to 
healthy, non-sleep deprived individuals, only moderate enhancements on attention 
(d=.56) were observed, with insufficient data to investigate effects on executive 
functions. Review of the current literature largely reflects these conclusions, as 
studies investigating the effects of modafinil on aspects of attention, executive 
functions and inhibitory control in samples of healthy, non-sleep deprived 
individuals, have largely produced mixed results.  
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In a double-blind, between subjects design, Turner et al. (2003) compared 
placebo to single doses of 100mg and 200mg of modafinil on an extensive battery of 
neuropsychological tests. In their sample of 60 healthy males, modafinil was shown 
to improve performance on tasks of digit span, visual pattern recognition, and spatial 
planning. Additionally, on the Stop-Signal paradigm, improvements in inhibitory 
control functions were indicated by both significantly reduced stop-signal reaction 
times (RTs) and significantly reduced error rates, suggesting modafinil both 
increased accuracy through the inhibition of reflexive responding whilst also 
increasing the efficiency and speed of the response (Turner et al., 2003). While 
dosage-dependent effects were not observed in other tasks, reduced stop-signal RTs 
and error rates were found for participants on 200mg of modafinil relative to those 
on 100mg. These findings were among the earliest to provide evidence for the 
enhancing effects of modafinil on executive functions, indicating a potential effect of 
selective enhancement of inhibitory control processes in healthy individuals. 
These effects, however, have not been so clearly replicated in ensuing 
studies. In a between-subjects design, Randall, Shneerson, Plaha, and File (2003) 
found no effects of modafinil on cognitive performance across a battery of 
neuropsychological tests in 30 healthy, non-sleep deprived students. Tasks included 
tests of working memory, spatial planning, sustained attention, and response 
inhibition, and revealed no differences between placebo, 100mg, and 200mg 
modafinil groups. In a following study, Randall, Fleck, Shneerson, and File (2004) 
again observed few effects of modafinil on performance in a battery of 
neuropsychological tests, this time within a sample of 45 non-sleep deprived, middle-
aged participants. A significant effect of modafinil was, however, observed on 
reduced time taken to complete the Stroop task for participants on 200mg of 
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modafinil, though this was observed only for the congruent, colour-naming 
component of the Stroop task, and not the incongruent word-naming component in 
which inhibition resources are necessary.  
Due to the relatively small sample sizes of these studies and potential lack of 
power to detect to significant effects between groups, a third study by Randall, et al. 
(2005b) again examined effects of modafinil on a neuropsychological test battery 
among 60 young, non-sleep deprived individuals. In addition to greater performance 
on tasks of digit span, pattern recognition, and a rapid visual information processing 
(RVIP) task of sustained attention; participants who ingested 200mg of modafinil 
also replicated previous findings of greater performance on the congruent component 
of the Stroop task (Randall et al., 2004; Randall, et al., 2005b). Again, these results 
provide little support for the role of modafinil in enhancing processes of inhibitory 
control, such as those demonstrated by Turner et al. (2003). Rather, enhancement 
processes appeared to be limited to enhanced sustained attention, indicating an effect 
of enhanced early processing or general vigilance, potentially as a result of 
combating day fatigue (Randall, et al., 2005b). 
While the effect of modafinil on enhancing behavioural correlates of 
inhibitory control in healthy, non-sleep deprived individuals remains unclear, 
imaging research has indicated that modafinil may have an impact on cortical 
activity within areas implicated in inhibitory control processes. While Rasetti et al. 
(2010) found no differences in performance on a Variable Attentional Control (VAC) 
task, fMRI analysis did indicate a significant decrease in BOLD signal within the 
anterior cingulate cortex (ACC) following 100mg modafinil ingestion relative to 
when participants ingested placebo. The VAC task involves focusing on arrows of 
three different sizes, with varying degrees of inhibitory control mediated by the 
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congruency of the cued target arrow with the direction of flanking arrows. Task load 
is increased from low, moderate to high depending on the size and congruency of the 
cued arrow in relation to its flankers. Despite observing no significant differences in 
accuracy or RT; increasing task load was associated with greater activation in the 
ACC for participants on placebo relative to modafinil. The ACC is an area richly 
innervated by catecholeminergic neurons, and is frequently implicated in executive 
functions including inhibitory control (Rasetti et al., 2010). A decrease in activity 
within the ACC during modafinil conditions was suggested to indicate increased 
cortical efficiency, with fewer resources necessary to attain similar levels of 
performance achieved in placebo conditions.  
Given that relatively low, 100mg doses of modafinil were used in this study, 
it is possible insufficient doses may account for the absence of behavioural 
differences on the VAC task, particularly since previous research has identified 
dosage-dependent effects in similar tasks (Turner et al., 2003; Wesensten, 2006). 
Additionally, the small sample of 11 participants to complete the VAC may have 
also presented problems with power sufficient to detect significant differences 
between conditions.   
Despite this, similar patterns have emerged from fMRI research by 
Minzenberg, Watrous, Yoon, Ursu, and Carter (2008), comparing prefrontal cortex 
(PFC) and locus coeruleus activity during a Preparing to Overcome Prepotency 
(POP) task of attentional inhibition and cognitive control. Similarly, while no effects 
on RT and accuracy were seen across the sample (n=22), significant task-dependent 
increases in PFC activity and PFC-LC functional connectivity were observed 
following ingestion of 200mg of modafinil relative to placebo. Similar to the ACC, 
these areas are considered to encompass catecholaminergic systems highly 
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implicated in functions of inhibitory and cognitive control. In a later study utilising 
the same POP task in conjunction with EEG, modafinil was also demonstrated to 
enhance oscillatory power in theta, alpha, and beta ranges at frontal and parietal 
electrode sites (Minzenberg et al., 2014). These middle frequency cortical 
oscillations have been implicated in a number of aspects of executive functioning, 
with alpha oscillations in particular considered to be associated with attentional, task-
focused inhibition (Jensen & Mazaheri, 2010; Minzenberg et al., 2014). 
Although no significant effects on POP task performance were observed in 
either the fMRI or EEG study, methodological limitations in these designs may 
account for the lack of apparent effects. Ceiling effects were problematic in both 
studies, and as a result behavioural effects of modafinil may have been more difficult 
to discern (Minzenberg et al., 2014; Minzenberg et al., 2008). For instance, 
Minzenberg et al. (2008) noted significant improvements in accuracy on incongruent 
POP trials in a sub-sample of 11 below-ceiling performers during the modafinil 
condition. Furthermore, repeated administration of the POP task in the EEG-based 
study resulted in practice effects occurring independently of drug and placebo 
condition, and as a result may have consequently concealed otherwise discernible 
effects of the drug (Minzenberg et al., 2014). When overall RT to both congruent and 
incongruent trials was compared across task blocks, significant decreases in RT were 
observed for modafinil but not placebo conditions (Minzenberg et al., 2014). 
In a recent systematic review on the cognitive enhancing effects of modafinil 
in healthy, non-sleep deprived populations, it was argued that methodological 
discrepancies throughout the literature likely account for a substantial proportion of 
the inconsistent findings (Battleday & Brem, 2015). In their review of 24 studies 
pertaining to processes of executive functions, attention, learning, memory and 
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creativity; Battleday and Brem (2015) reported that within studies utilising basic 
testing paradigms, enhancements of executive functions are frequently observed, 
though improvements in attention, learning and memory are seen to a lesser degree. 
When complex assessment paradigms are used however, modafinil is suggested to 
consistently enhance processes of attention, learning and executive functions. 
Complex tasks are described as novel paradigms developed for the assessment of 
higher order functions and global cognitive domains, as opposed to the direct 
assessment of specific sub-functions, such as inhibitory control. 
 Battleday and Brem (2015) suggest that the complexity of task paradigms 
utilised in studies attempting to identify neuroenhancement is a major factor in the 
detection of significant effects. Given that many of the paradigms were originally 
developed for clinical populations, ceiling effects become an issue when attempting 
to investigate enhanced performance in healthy populations. The effect of ceiling 
performance in placebo controls also offers some explanation as to why 
electrophysiological or imaging techniques may reveal group or condition-based 
differences in the absence of differences in behavioural performance (Minzenberg et 
al., 2014; Minzenberg et al., 2008; Rasetti et al., 2010). Battleday and Brem (2015) 
argue that in studies assessing performance on novel and more complex tasks, 
cognitive enhancing effects of modafinil are more readily observable. Issues with 
this approach do arise however, given that novel and complex tasks are often less 
well standardised than the ‘simple tasks’ critiqued within the review, and typically 
provide less evidence on effects of specific and well-described functions such as 
inhibitory control. 
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Electrophysiological Correlates of Inhibitory Control 
There remains a substantial lack of research utilising electrophysiological 
techniques to examine the potential effects of modafinil on enhancement of cognitive 
processes, particularly in healthy, non-sleep deprived individuals. Given the 
extensive, yet equivocal research surrounding the effect of modafinil on processes of 
inhibitory control, the utilisation of more temporally precise measures may provide 
further insight regarding the extent to which modafinil may specifically enhance 
these processes.  
Event-related potentials (ERPs) allow for the investigation of neural 
correlates of particular cognitive processes with high temporal resolution, enabling 
neural activity to be tracked on a scale of milliseconds (Pires, Leitao, Guerrini, & 
Simoes, 2014). The anterior N2 component is a negative deflection that peaks 
approximately 200-350ms post-stimulus onset, and has been suggested to be 
modulated by functions of cognitive and executive control (Folstein & Van Petten, 
2008). In particular, the anterior N2 component is proposed to index processes of 
frontal inhibitory control, suggested to derive from areas of the PFC and ACC 
(Falkenstein, 2006; Folstein & Van Petten, 2008). The classical paradigm in which 
these effects are observed is the Go/Nogo task, in which participants must respond to 
one class of stimuli and withhold response to a second class of stimuli. Greater N2 
amplitude is hence observable on the ‘nogo’ trials of response inhibition, referred to 
as the nogo-N2 effect (Falkenstein, 2006). The Eriksen flanker task is also a common 
paradigm used to elicit the N2 component, by which participants respond to a central 
letter surrounded by either congruent, identical letters, or incongruent letters that 
differ from the target. Again, greater N2 amplitude is observed on trials where 
participants must inhibit interference of incongruent ‘flanking’ letters (Heil, Osman, 
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Wiegelmann, Rolke, & Hennighausen, 2000). The combined Flanker Go/Nogo 
paradigm incorporates aspects of both tasks, with enhanced N2 amplitude observable 
on both congruent nogo trials and incongruent go trials relative to congruent go 
trials. In this paradigm, the N2 component is particularly enhanced on incongruent, 
nogo trials, where both inhibition of flanker interference and inhibition of response 
are necessary (Heil et al., 2000). 
In populations where inhibitory control deficits are thought to occur, reduced 
N2 amplitude is observed when utilising these paradigms. Johnstone, Barry, 
Markovoska, Dimoska, and Clarke (2009) demonstrated that in children with ADHD, 
significantly reduced N2 amplitude is observed during nogo trials of the Go/Nogo 
task, and to incongruent stimuli of the Flanker task, relative to children in the control 
group. Similar findings have also been demonstrated in chronic cannabis users, 
where significant reductions in N2 amplitude on nogo, and particularly nogo 
incongruent trials on the Flanker Go/Nogo paradigm, were observed relative to drug 
naive controls (Nicholls, Bruno, & Matthews, 2015). The effect of modafinil on the 
N2 component remains an unexplored issue, with no studies to date attempting to 
utilise ERPs to investigate effects in this area. 
Rationale, Aim and Hypotheses 
 Given the varying evidence for the enhancing effect of modafinil on 
inhibitory control processes in healthy, non-sleep deprived populations, the present 
study aims to specifically elucidate the effect of modafinil on this primary executive 
function. As fMRI and EEG research has indicated effects may occur neurologically 
in the absence of apparent behavioural differences (Minzenberg et al., 2014; 
Minzenberg et al., 2008; Rasetti et al., 2010), the present study intended to expand 
upon previous literature by utilising ERP techniques to acquire temporally precise 
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indices of an inhibitory control mechanism. The present study used a Flanker 
Go/Nogo paradigm due to being a well standardised measure of inhibitory control 
and effective in elicitation of the N2 component. In consideration of task complexity 
and ceiling effects, task difficulty was maximised through brief stimulus 
presentations and the utilisation of phonologically and visually similar target and 
distracter stimuli.  
In sum, it was therefore the aim of the present study to utilise a Flanker 
Go/Nogo paradigm to investigate the effect of a 200mg dosage of modafinil on both 
behavioural and ERP correlates of inhibitory control in a sample of healthy, non-
sleep deprived individuals. Specifically, differences in RT, accuracy, and amplitude 
of the anterior N2 component were compared across conditions influenced by either 
a single-dose of modafinil or placebo. 
It was firstly hypothesised that on the Flanker Go/Nogo paradigm, 
participants would exhibit significantly slower reaction times (RTs) for incongruent 
stimuli relative to congruent stimuli. If modafinil does enhance inhibitory control 
processes, it is expected that at post-ingestion testing, this increase will be 
significantly reduced in participants under the modafinil condition relative to the 
placebo condition. The second hypothesis was that across go/nogo trial types, a 
significant reduction in accuracy would be observed for incongruent stimuli relative 
to congruent stimuli. Again, if modafinil enhances inhibitory control, this reduction 
is expected to be significantly less for participants under the modafinil condition 
compared to placebo conditions at post-ingestion testing. The final hypothesis was 
that the increase in N2 amplitude between go and nogo trials (nogo effect) was 
expected to be significantly greater for incongruent stimuli relative to congruent 
stimuli. Again, if modafinil enhances inhibitory control, this enhancement of N2 
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amplitude is in turn expected to be significantly greater for participants under the 
modafinil condition relative to the placebo condition.  
Method 
Participants 
 An a priori power analysis indicated that a sample of nineteen participants 
were sufficient for the detection of a moderate effect size (f = .25) at a power of 0.8. 
Nineteen male participants aged 19-27 were recruited for the study. One participant 
was excluded due to not completing both sessions, resulting in a final sample of 18 
participants. 
Exclusion criteria included: being female; any use of illicit drugs in the past 
month or a history of frequent use; regular tobacco use; current use of any prescribed 
medications; any current neurological, physical or psychological conditions; alcohol 
dependence or abuse as measured by the Alcohol Use and Disorders Identification 
Test (AUDIT; Babor, Higgens-Biddle, Saunders, Monteiro, 2001; defined as scores 
≥ 16); high levels of psychological distress as measured by the Kessler Psychological 
Scale (K10; Kessler, 2002; defined as scores ≥ 30); risk of psychosis as identified by 
the Psychosis Screener (Degenhardt, Wall, Korten & Jablensky, 2005; defined as 
scores ≥ 1) and the Schizotypal Personality Questionnaire-Brief (SPQ-B; Raine & 
Benishay, 1995; defined as scores ≥ 17); and daily use of paracetamol or ibuprofen. 
Participants were also excluded based on a BMI lower than 18 and history of adverse 
reactions to caffeinated beverages. Fluent English was also a requirement due to the 
linguistic stimuli used in the cognitive task. Participants were asked to abstain from 
alcohol 24hrs prior to testing, and paracetamol and ibuprofen on the day of testing. 
Participants were asked to consume caffeine as normal, and to eat a light lunch prior 
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to arriving at the experimental session between 12pm and 1pm. It was also necessary 
that participants pre-organise transportation home for the end of each session. 
Participants were recruited via advertisement around the University of 
Tasmania, peer referral, and advertisement to the first year psychology cohort (via 
SONA online research participation system). Interested applicants contacted 
researchers via SMS or email, and were contacted for a preliminary screening via 
telephone. Participants were reimbursed $80 for time and expenses, and first year 
psychology students had the option of either $80 reimbursement, or partial course 
credit and partial reimbursement. At the beginning of the first session, all participants 
were provided with an information sheet, and written informed consent was obtained 
(see Appendix A). The study was approved by the Tasmania Health & Medical 
Human Research Ethics Committee (see Appendix B).  
Materials 
 Questionnaire Measures. A standardised screening questionnaire included 
questions pertaining to: demographic information; history of illicit drug use; tobacco 
use; current medications; history of neurological, physical or psychological 
conditions; caffeine consumption; BMI; first-spoken language; and handedness. An 
experimental session questionnaire (see Appendix C) was used at the beginning of 
each session, including questions pertaining to: recent caffeine, nicotine, alcohol, 
drug, and medication use; food consumption; hours slept; and measurement of BMI. 
A side effect checklist (see Appendix D) was provided at the end of each session, 
comprising a Yes/No checklist of commonly reported side effects (MIMS, 2009), 
and space to report any additional adverse effects.  
 The Alcohol Use and Disorders Identification Test (AUDIT; Babor et al., 
2001) was used to identify problematic consumption of alcohol within the past 12 
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months, with scores ≥ 16 indicating potential alcohol dependence. The AUDIT 
comprises 10 questions aimed at identifying hazardous alcohol use, alcohol 
dependence symptoms, and alcohol-related problems, and has demonstrated efficacy 
across age, gender and culture (Babor et al., 2001). 
 The Kessler Psychological Distress Scale (K10; Kessler et al., 2002) is a 10-
item scale which was used to detect psychological wellbeing over the past 4 weeks. 
Questions regarding experiences of psychological distress were answered on a 5-
point Likert scale ranging from 1 (none of the time) to 5 (all of the time), with scores 
of 30 or more indicating a very high level of psychological distress (ABS, 2007). The 
psychometric properties of the K10 have been validated for use across a range of 
sociodemographic samples (Kessler et al., 2002). 
 The Psychosis Screener (Degenhardt et al., 2005) is a brief 7-item measure 
used to identify features of psychotic disorders, with scores ≥ 1 indicating potential 
psychosis. This was used in conjunction with the Schizotypal Personality 
Questionnaire-Brief (SPQ-B; Raine & Benishay, 1995), a 22-item scale in which 
scores ≥ 17 indicate a disposition to schizotypal traits. 
The Profile of Mood States-Short Form (POMS-SF; Shacham, 1983) was 
used as a pre- and post-ingestion measure of mood states. Ratings are provided on 
the subjective appropriateness of 37 different mood states using 5-point Likert scales 
ranging from ‘not at all’ to ‘extremely’. The scale consists of nine subscales, 
pertaining to Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigour-
Activity, Fatigue-Inertia, and Confusion-Bewilderment. Total mood disturbance is 
calculated from the sum of all subscales, ranging from scores of 0-148. 
The Karolinska Sleepiness Scale (KSS; Åkerstedt & Gillberg, 1990) is a 9-
point measure of subjective sleepiness, and was used as a pre- and post-ingestion 
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measure during each session. The scale ranges from ‘extremely alert’ to ‘very sleepy, 
great effort to keep awake, fighting sleep’, with higher scores indicating a greater 
level of sleepiness. 
The Weschler Test of Adult Reading (WTAR; Weschler, 2001) is a test of 
verbal intelligence comprising 50 irregularly spelled words of which participants are 
required to correctly pronounce. Final raw scores reflect the number of correctly 
pronounced words, and are converted to standardised scores based on age. 
Standardised scores correlate strongly with overall verbal IQ (r = .75) and full-scale 
IQ (r = .73; Weschler, 2001). 
Visual Analogue Scales (VAS; see Appendix E) of Subjective Performance 
were used as pre- and post-ingestion measures in which participants mark a point 
along a 10cm continuum according to their extent of agreement with the item, 
ranging from ‘strongly agree’ to ‘strongly disagree’. Lower scores indicated greater 
levels of agreement with the item. Items related to feelings of alertness, confidence in 
performing cognitive tasks, and confidence in driving ability in each experimental 
session. VAS of Subjective Drug Effects were used post-ingestion in both 
experimental sessions, with items relating to strength of drug effect, liking of drug 
effect, alertness, and intoxication. Higher scores indicated a greater drug effect. 
 Flanker Go/Nogo paradigm. In the Flanker Go/Nogo paradigm (adapted 
from Nicholls, Bruno & Matthews, 2015), the Erikson flanker task (Eriksen & 
Eriksen, 1974) is combined with the go/nogo response paradigm. Within each trial, a 
fixation cross was first presented for 300ms, followed by a letter string comprising 
five white-font uppercase letters (subtending 2.0° x 8.0°) with a duration of 250ms. 
Inter-trial intervals ranged from 1550ms to 1950ms in 100ms increments. 
Participants were required to focus on the middle letter of each letter string stimulus 
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and respond with their left or right index finger upon presentation of a ‘B’ or ‘C’ 
stimulus (go trial), respectively. Participants were required to withhold their response 
upon presentation of a ‘D’ or ‘G’ stimulus (nogo trial). Centre letters of the letter-
string stimuli were flanked with either congruent (BBBBB) or incongruent 
(DDBDD) distracter letters. Go versus nogo trials and congruent versus incongruent 
stimuli were each presented with equal probability. The experimental task in total 
comprised one practice block of 10 trials, and four experimental blocks of 100 trials 
each. At the beginning of each session, a shortened, 100-trial baseline task was 
administered in order to assess within-day behavioural performance from pre- to 
post-ingestion, and to control for practice effects across sessions. 
 Electrophysiological (EEG) recording. Cognitive tasks were presented on a 
computer using the NeuroSCAN Stim2 software. EEG activity was simultaneously 
recorded using the NeuroSCAN 4.54 system and a 32-channel Quik-Cap with 
Ag/AgCl sintered electrodes. According to the international 10-20 system of 
electrode placement, continuous EEG data was recorded from 32 sites at a rate of 
1000Hz. Electrodes were referenced to linked mastoids, and electrode impedance 
was kept below 10kΩ. Horizontal electro-oculographic (EOG) activity was recorded 
from the outer canthi of both eyes, and vertical EOG activity recorded from above 
and below the left eye.  
 During editing, behavioural data was merged with continuous EEG files and 
subsequently filtered using a Zero-phase-shift low-pass filter (30Hz, 24dB/Oct). 
Ocular artefact reduction (via an artefact averaging and reduction procedure) was 
then performed to control the effect of eye blinks on other electrode channels. Data 
epochs were then extracted from 100ms before stimulus onset to 900ms post-
stimulus. Baseline correction and artefact rejection was subsequently conducted, with 
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trials containing artefacts above 70 μV or below -70 μV removed. The fronto-central 
peak N2 component was determined from grand averaged waveforms and was 
defined as the maximum amplitude 240-360ms post-stimulus onset. An automatic 
peak detection process was then performed, followed by manual corrections. 
Randomisation and blinding 
 To ensure blinding of participants and experimenters, the randomisation of 
drug condition was conducted by an independent researcher prior to the recruitment 
of any participants, and was determined by a randomisation schedule from 
randomization.com. Upon establishing eligibility, participants were assigned a 
unique code based on sequence of presentation, each of which corresponded to pre-
packed envelopes determining order of drug condition over the two sessions. This 
order was counterbalanced across participants, so that half the sample would ingest 
modafinil in the first session, and the other half, placebo. Both modafinil and placebo 
capsules were matched for size, shape and colour, so that neither participants nor 
experimenters may discern differences. Modafinil capsules were each filled with 
gluten-free cornflower and a 100mg tablet of modafinil, whereas placebo capsules 
were filled only with gluten-free cornflower.  
Procedure 
 After screening, eligible participants were invited to attend two experimental 
sessions at the University of Tasmania, over which they were tested under the 
influence of both placebo and 200mg of modafinil. All sessions began between 12pm 
and 1pm, and each lasted 4 hours. Within-participant sessions were separated by at 
least 1 week in order to control for any residual effects of modafinil if ingested 
during the first session. After providing informed consent at the beginning of the first 
session, participants underwent secondary screening to confirm eligibility. This 
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included completion of the AUDIT, the K10, the SPQ-B, the experimental session 
questionnaire, and measurement of BMI. 
Participants then completed the POMS-SF, KSS, WTAR, VAS, and a 
shortened (100 trial) Flanker Go/Nogo baseline task. Subsequently, either 200mg of 
modafinil or placebo was administered (two capsules), as per the predetermined 
order. This was followed by a 2 hour interval prior to EEG setup, ensuring cognitive 
testing occurred during modafinil peak plasma levels, 2-4 hours post-ingestion 
(Minzenberg & Carter, 2008). During this break participants were able to relax in a 
private room where they could read, study or watch television, though were regularly 
checked on. At 2 hours post-ingestion participants underwent setup for EEG 
recording and were afterward seated in front of a computer, ready to begin testing at 
2.5 hours post-ingestion. During cognitive testing, participants completed two tasks 
in counterbalanced order (one of which is not reported in the present study) lasting 
approximately 45 minutes in total. Participants were instructed to respond as quickly 
and accurately as possible whilst minimising eye and body movements. When 
finished, participants completed the post-ingestion POMS-SF, KSS and VAS, before 
being dismissed. At the end of their second session, participants received a complete 
debriefing and were reimbursed for their time and out-of-pocket expenses.  
Design and Data Analysis 
 The data was assessed to ensure the assumptions of ANOVA had been met. 
Any individual RTs greater than 3 standard deviations above the participants’ mean 
were recognised as outliers and excluded from the analysis. An accuracy cut-off of 
less than 75% was used to determine outliers within the accuracy data, with no 
exclusions found to be necessary. Baseline measures and VAS of Subjective Drug 
Effects were compared using paired samples t-tests. The POMS-SF subscales, KSS, 
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and VAS of Subjective Performance were analysed using 2 (Drug Condition: 
modafinil, placebo) x 2 (Time: pre-ingestion, post-ingestion) repeated measures 
ANOVAs.  
 Behavioural dependent variables for the Flanker Go/Nogo task were RT (ms) 
and accuracy (% of correct responses). RT was analysed using a 2 (Drug Condition: 
modafinil, placebo) x 2 (Time: pre-ingestion, post-ingestion) x 2 (Congruency: 
congruent, incongruent) repeated measures ANOVA on correct ‘go’ trials of the task. 
Accuracy was analysed using a 2 (Drug Condition: modafinil, placebo) x 2 (Time: 
pre-ingestion, post-ingestion) x 2 (Trial Type: go, nogo) x 2 (Congruency: congruent, 
incongruent) repeated measures ANOVA. For the accuracy data, only significant or 
theoretically relevant non-significant main effects and interactions are reported. 
 The electrophysiological dependent variable was peak amplitude of the N2 
component of the ERP waveform. Consistent with previous literature, preliminary 
analyses showed that N2 amplitude was maximal at frontal electrode sites, and 
analyses were restricted to the midline frontal site (Fz). Analysis of N2 amplitude 
was achieved using a 2 (Drug Condition: modafinil, placebo) x 2 (Trial Type: go, 
nogo) x 2 (Congruency: congruent, incongruent) repeated measures ANOVA. 
 Any significant interactions were followed up using Bonferroni corrected 
pair-wise comparisons in order to maintain a Type 1 error rate of less than 5%. Effect 
sizes were measured using partial eta squared (ƞp
2
) for any omnibus ANOVAs, and 
Hedge’s g for any tests of simple effects. Magnitude of effect for Hedge’s g was 
interpreted using Cohen’s (1992) convention of small (0.2), moderate (.05), and large 
(0.8), and for ƞp
2
, the convention of small (0.01), moderate (0.06) and large (0.14).  
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Results 
Demographic and Screening Variables  
 Table 1 shows mean age, demographics and scores on questionnaire 
measures. Analysis of demographic and screening variables indicated that the sample 
were largely university educated, of average intelligence (as measured by the 
WTAR), and in a healthy weight range. Problematic alcohol use (as measured by the 
AUDIT), psychological distress (as measured by the K10), and risk of psychosis (as 
measured by the psychosis screener and SPQ-B) were all identified as within the low 
risk range.  
Baseline Measures, Side Effects and Blinding 
 Variables with the potential to confound the results were compared at 
baseline between each drug condition and are displayed in Table 2. No significant 
differences were observed between the modafinil and placebo conditions on prior 
caffeine intake, hours of sleep the previous night, baseline sleepiness (as measured 
by the KSS), or baseline mood disturbance (as measured by the POMS-SF). 
Mcnemar tests were conducted on the proportion of participants to report each item 
on the side effect checklist, with no significant differences between the conditions. 
Four participants in the modafinil condition did, however, report additional adverse 
effects of minor shakiness; minor visual disturbance/hallucination while completing 
tasks; neck and jaw tension; and increased heart rate and breathing accompanied by 
shakiness. Follow up inquiry indicated that none of the participants found the 
symptoms to be severe or distressing, and no intervention was required.   
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Table 1  
Means and Standard Deviations for Demographic and Screening Variables 
 
Variable 
 
 
M 
 
SD 
 
Range 
 
Age (years) 
 
21.40 
 
2.33 
 
19-27 
 
Level of Education (% completed Year 12) 
 
100% 
 
n/a 
 
n/a 
 
Level of Education (% commenced/completed tertiary) 
 
88.9% 
 
n/a 
 
n/a 
 
Handedness (% right handed) 
 
83.3% 
 
n/a 
 
n/a 
 
Caffeine Use (% ≥ 2 times per week) 
 
77.7% 
 
n/a 
 
n/a 
 
BMI 
 
23.0 
 
4.20 
 
18-34 
 
Problematic Alcohol Use (AUDIT) 
 
3.83 
 
2.96 
 
0-10 
 
Psychological Distress (K10) 
 
13.24 
 
4.88 
 
0-23 
 
Risk of Psychosis (SPQ-B) 
 
3.53 
 
4.94 
 
0-17 
 
General Intellectual Functioning (WTAR standard 
score) 
 
 
104.6 
 
9.5 
 
82-118 
 
A Wilcoxin’s Signed Rank test on blinding indicated that confidence of 
ingesting modafinil was significantly higher in the modafinil condition (Mdn=50.0%) 
relative to the placebo condition (Mdn=17.5%), T=19.5, p=.021, r=-.054. Confidence 
ratings were, however, highly variable between participants in both conditions, with 
ranges of 0% to 100% in the modafinil condition, and 0% to 80% in the placebo 
condition.    
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Table 2 
Means (Standard Deviations) and Paired Samples t-Tests for Control Variables at 
Pre-Ingestion and Mcnemar Tests for Reported Side Effects at Post-Ingestion 
 
Control Variable 
 
Modafinil  
 
Placebo  
 
t 
 
p 
 
g 
 
Caffeine Intake (per drink) 
 
.50 (.86) 
 
.61 (.78) 
 
.81 
 
.430 
 
.13 
 
Prior Sleep (hours) 
 
7.47 (1.06) 
 
7.67 (1.22) 
 
.73 
 
.474 
 
.17 
 
Sleepiness (KSS) 
 
4.72 (1.02) 
 
4.67 (1.24) 
 
.18 
 
.859 
 
.05 
 
Total Mood Disturbance 
(POMS-SF) 
 
17.72 (10.94) 
 
17.06 (10.54) 
 
.49 
 
.634 
 
.06 
 
Side Effect Checklist 
     
 
    Headache 
 
5.6% 
 
16.7% 
 
 
 
.625 
 
 
 
    Nausea 
 
0% 
 
11.1% 
 
 
 
.500 
 
 
 
    Dry Mouth 
 
38.9% 
 
11.1% 
 
 
 
.063 
 
 
 
    Runny Nose  
 
0% 
 
5.6% 
 
 
 
1.00 
 
 
 
    Sore Throat 
 
0% 
 
0% 
 
 
 
n/a 
 
 
 
    Nervousness 
 
11.1% 
 
5.6% 
 
 
 
1.00 
 
 
 
    Dizziness 
 
16.7% 
 
11.1% 
 
 
 
1.00 
 
 
 
Note: POMS-SF Total Mood Disturbance ranges from 0-148, with higher scores indicating greater 
overall mood disturbance. For side effects, data displayed reflect the percentage of the sample to 
report the respective item. 
 
Mood and Sleepiness 
 Table 3 shows the means and standard deviations for each time point on the 
POMS-SF and KSS. Analysis the POMS-SF subscales revealed a significant main 
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effect of Drug Condition for the Vigour-Activity subscale, F(1,17)=8.86, p=.008, 
ƞp
2
=.343. This effect was subsumed by a significant Drug Condition x Time 
interaction, F(1,17)=15.68, p=.001, ƞp
2
=.480, indicating that for the placebo 
condition, there was a significant reduction in scores from pre-ingestion to post-
ingestion (p<.001, g=.99), with no significant differences in the modafinil condition 
(p=.325, g=.21). A significant main effect of Time was found for the Fatigue-Inertia 
subscale, F(1,17)=16.61, p=.001, ƞp
2
=.494. Again, this effect was encompassed 
within a significant Drug Condition x Time interaction, F(1,17)=4.90, p=.041, 
ƞp
2
=.224, indicating that for the placebo condition, there was a significant increase in 
scores from pre-ingestion to post-ingestion (p<.001, g=.1.23), with no significant 
difference in the modafinil condition (p=.184, g=.45). A significant Drug Condition 
x Time interaction was also observed for the Depression-Dejection subscale, 
F(1,17)=4.83, p=.042, ƞp
2
=.221, indicating that for the modafinil condition, there was 
a significant reduction in scores from pre-ingestion to post-ingestion (p=.015, g=.88), 
with no significant differences from pre-ingestion to post-ingestion in the placebo 
condition (p=.933, g=.02). No other significant main effects or interactions were 
found for any of the other POMS-SF subscales (p>.05).   
Analysis of the KSS revealed a significant main effect of Drug Condition, 
F(1,17)=12.78, p=.002, ƞp
2
=.429, and a non-significant main effect of Time, 
F(1,17)=2.70, p=.188, ƞp
2
=.137. These effects were however qualified within a 
significant Drug Condition x Time interaction, F(1,17)=9.57, p=.007, ƞp
2
=.360, 
revealing a significant increase in sleepiness for the placebo condition from pre-
ingestion to post-ingestion (p=.001, g=1.07), with no significant changes in 
sleepiness from pre-ingestion to post-ingestion for the modafinil condition (p=.859, 
g=.34). 
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Table 3 
Means (and Standard Deviations) for the POMS-SF Subscales and KSS at Pre-
Ingestion and Post-Ingestion  
  
Modafinil 
 
Placebo 
 Pre-
ingestion 
Post-
ingestion 
Pre-
ingestion 
Post-
ingestion 
 
 
POMS-SF subscales 
    
 
     Tension-Anxiety 
 
3.00 (3.46) 
 
3.72 (5.07) 
 
2.89 (3.60) 
 
2.00 (2.95) 
 
     Depression-Dejection 
 
1.33 (2.09) 
 
.00 (.00) 
 
1.22 (2.21) 
 
1.28 (3.27) 
 
     Anger-Hostility 
 
.28 (1.18) 
 
.06 (.24) 
 
.33 (.69) 
 
.28 (1.00) 
 
     Vigour-Activity 
 
8.50 (5.92) 
 
9.83 (6.21) 
 
8.61 (4.59) 
 
4.44 (3.62) 
 
     Fatigue-Inertia 
 
2.83 (2.81) 
 
4.28 (3.37) 
 
1.94 (2.01) 
 
6.44 (4.63) 
 
     Confusion-
Bewilderment 
 
1.78 (2.16) 
 
1.83 (2.92) 
 
2.06 (3.08) 
 
2.33 (3.12) 
 
Sleepiness (KSS) 
 
4.72 (1.02) 
 
4.22 (1.73) 
 
4.67 (1.24) 
 
6.11 (1.41) 
 
Note: Score ranges for POMS-SF subscales are: Tension-Anxiety ranges 0-24, Depression Dejection 
ranges 0-32, Anger-Hostility ranges 0-28, Vigour-Activity ranges 0-24, Fatigue Inertia ranges 0-20, 
and Confusion-Bewilderment ranges 0-20. For each subscale, higher scores indicate greater levels of 
specified mood. For the KSS, higher scores indicate greater levels of sleepiness. 
 
Alertness 
Descriptive statistics for the VAS of Subjective Performance and VAS of 
Subjective Drug Effects are displayed in Table 4. Analysis of the VAS of Subjective 
Performance revealed significant main effects of Time on the ‘I do not feel that my 
driving would be impaired right now’ item, F(1,17)=13.00, p=.002, ƞp
2
=.433, with a 
significant increase at pre-ingestion (M=1.46, SD=2.08) relative to post-ingestion 
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(M=3.39, SD=2.41), and the ‘I feel capable of driving safely right now’ item, 
F(1,17)=17.03, p=.001, ƞp
2
=.500, with a significant increase at pre-ingestion 
(M=1.04, SD=2.04) relative to post-ingestion (M=2.71, SD=2.46). A significant main 
effect of Drug Condition was found on the ‘I feel alert’ item, F(1,17)=11.10, p=.004, 
ƞp
2
=.395, which was subsumed by a significant Drug Condition x Time interaction, 
F(1,17)=7.94, p=.012, ƞp
2
=.318. This interaction indicated that while there were no 
significant differences between pre-ingestion and post-ingestion for the modafinil 
condition (p=.189, g=.42), there was a significant decrease for the placebo condition 
(p=.034, g=.72) that did not maintain significance following a Bonferroni correction 
(α=.025). On the ‘I feel that I will be able to perform the attention tasks to the best of 
my ability’ item, there were main effects of Drug Condition, F(1,17)=7.56, p=.014, 
ƞp
2
=.308, Time, F(1,17)=23.26, p<.001, ƞp
2
=.577, and a significant Drug x Time 
interaction, F(1,17)=8.71, p=.009, ƞp
2
=.339, by which there was a significant 
decrease in agreement from pre-ingestion to post-ingestion for the placebo (p<.001, 
g=1.34), but not the modafinil condition (p=.307, g=.27). No other significant main 
effects or interactions were found on the VAS of Subjective Performance (p>.05).  
Analysis of the VAS of Subjective Drug Effects revealed a significant main 
effect on the ‘Strength of drug effect’ item, with significantly greater strength 
indicated in the modafinil relative to placebo condition, t(17)=2.15, p=.046, g=.60. A 
significant main effect was also found for the ‘Liking of drug effect item’ with 
significantly greater ratings in the modafinil relative to placebo condition, 
t(17)=2.75, p=.012, g=.82. Consistent with the VAS of Subjective Performance, a 
significant main effect was also observed for the ‘Alert level’ item with greater 
alertness indicated by the modafinil relative to placebo condition, t(17)=3.19, 
29 
 
 
p=.005, g=.83. No significant differences were observed for the ‘Intoxication’ item, 
t(17)=.63, p=.538, g=.18.  
 
Table 4 
Means (and Standard Deviations) for the VAS of Subjective Performance at Pre-Ingestion 
and Post-Ingestion, and VAS of Subjective Drug Effects at Post-Ingestion  
  
Modafinil 
 
Placebo 
 Pre-
ingestion 
Post-
ingestion 
Pre-
ingestion 
Post-
ingestion 
 
 
VAS of Subjective 
Performance 
    
 
     I feel alert 
 
3.63 (1.09) 
 
2.89 (2.16) 
 
3.73 (1.45) 
 
5.08 (2.15) 
 
     Ability for attention tasks 
 
2.34 (1.26) 
 
2.84 (2.24) 
 
2.58 (1.16) 
 
4.84 (2.03) 
 
     Unimpaired driving  
 
1.47 (2.38) 
 
2.97 (2.56) 
 
1.45 (2.12) 
 
3.81 (3.04) 
 
     Capable of driving safe 
 
.96 (1.89) 
 
2.63 (2.86) 
 
1.12 (2.60) 
 
2.81 (2.92) 
 
VAS of Subjective Drug 
Effects 
 
 
 
 
 
 
 
 
 
     Strength of drug effect 
 
 
 
3.63 (2.95) 
 
 
 
2.04 (2.17) 
 
     Liking of the drug effect 
 
 
 
5.75 (2.06) 
 
 
 
4.05 (1.05) 
 
     Alert level 
 
 
 
5.99 (2.65) 
 
 
 
3.94 (2.12) 
 
     Intoxication 
 
 
 
1.27 (1.91) 
 
 
 
.92 (1.79) 
 
Note: Scores range from 0 – 10. For the VAS of Subjective Performance, lower scores indicate more 
agreement with the item. For the VAS of Subjective Drug Effects, higher scores indicate a greater 
degree of the item (e.g. higher score equals stronger drug effect). 
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Reaction Time 
 Table 5 shows the mean RTs between Drug Condition for each of the ‘go’ 
trials in the Flanker Go/Nogo task. Analysis of RT (ms) revealed a significant main 
effect of Congruency, F(1,17)=63.28, p<.001, ƞp
2
=.788, with significantly slower 
RTs for incongruent stimuli (M=485, SD=44) relative to congruent stimuli (M=454, 
SD=46). There was also a significant main effect of Time, F(1,17)=6.67, p=.016, 
ƞp
2
=.282, with participants demonstrating significantly faster RTs at post-ingestion 
(M=459, SD=41) compared to pre-ingestion (M=480, SD=53). A non-significant 
main effect was observed for Drug Condition, F(1,17)=.08, p=.930, ƞp
2
<.001, 
indicating there were no overall differences in RT between the modafinil (M=470, 
SD=49) and placebo conditions (M=469, SD=50). A trend towards significance was 
however observed for the Drug Condition x Time interaction, F(1,17)=4.27, p=.054, 
ƞp
2
=.202, and due to its near significance and large size of effect, Bonferroni 
corrected tests of simple main effects were conducted. Displayed in Figure 1, pair-
wise comparisons revealed a significant decrease in RT from pre-ingestion to post-
ingestion for the modafinil condition (p=.016, g=.56), with no significant differences 
between pre-ingestion and post-ingestion in the placebo condition (p=.170, g=.18). 
The Drug Condition x Congruency interaction, F(1,17)=.18, p=.676, ƞp
2
=.011, the 
Time x Congruency interaction, F(1,17)=2.27, p=.150, ƞp
2
=.118, and the 
hypothesised three way Drug Condition x Time x Congruency interaction, 
F(1,17)=.26, p=.616, ƞp
2
=.015, were all non-significant. 
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Table 5 
Means (Standard Deviations) and 95% CIs for Reaction Time (ms) at Pre-Ingestion 
and Post-Ingestion 
  
Modafinil 
 
Placebo 
 M (SD) 95% CI M (SD) 95% CI 
 
 
Pre-ingestion 
    
 
     Go Congruent 
 
468 (66) 
 
[435, 501] 
 
458 (60) 
 
[428, 488] 
 
     Go Incongruent 
 
503 (68) 
 
[470, 537] 
 
490 (54) 
 
[463, 516] 
 
Post-ingestion  
 
 
 
 
 
 
 
 
 
     Go Congruent 
 
440 (42) 
 
[420, 461] 
 
451 (50) 
 
[426, 475] 
 
     Go Incongruent 
 
468 (42) 
 
[447, 489] 
 
478 (50) 
 
[453, 503] 
 
 
 
Figure 1. Mean reaction times (ms) for modafinil and placebo conditions at pre-
ingestion and post-ingestion time points (error bars indicate 95% CIs) 
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Accuracy 
Descriptive statistics for accuracy (% of correct responses) for each condition 
are displayed in Table 6. Analysis of accuracy showed a significant main effect of 
Trial Type, F(1,17)=25.35, p<.001, ƞp
2
=.599, whereby greater accuracy was 
observed for nogo trials (M=98.08, SD=1.65) relative to go trials (M=94.75, 
SD=2.93). A significant main effect of Congruency, F(1,17)=8.24, p=.011, ƞp
2
=.326, 
indicated lower accuracy for incongruent stimuli (M=95.91, SD=2.27) relative to 
congruent stimuli (M=96.92, SD=1.85). The main effect of Time was non-
significant, F(1,17)=.25, p=.624, ƞp
2
=.014, as was the main effect of Drug Condition, 
F(1,17)=.01, p=.950, ƞp
2
<.001. No significant interactions were observed for Drug 
Condition x Congruency, F(1,17)=.01, p=.916, ƞp
2
=.001, Drug Condition x Trial 
Type, F(1,17)=3.50, p=.079, ƞp
2
=.171, or Drug Condition x Time, F(1,17)=1.93, 
p=.183, ƞp
2
=.102. The three way Drug Condition x Congruency x Time interaction 
was also non-significant, F(1,17)=.02, p=.885, ƞp
2
=.001. No other significant main 
effects or interactions were found (p>.05). 
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Table 6 
Means (Standard Deviations) and 95% CIs for Accuracy (% of correct responses) at 
Pre-Ingestion and Post-Ingestion 
  
Modafinil 
 
Placebo 
 M (SD) 95% CI M (SD) 95% CI 
 
 
Pre-ingestion 
    
 
    Go Congruent 
 
94.31 
(5.06) 
 
[91.79, 96.82] 
 
95.83 
(5.75) 
 
[94.39, 97.83] 
 
    NoGo Congruent 
 
98.47 
(2.12) 
 
[97.42, 99.53] 
 
98.19 
(4.00) 
 
[96.20, 100.19] 
 
    Go Incongruent 
 
94.31 
(3.72) 
 
[92.46, 96.16] 
 
96.11 
(3.45) 
 
[94.39, 97.83] 
 
    NoGo Incongruent 
 
98.06 
(2.91) 
 
[96.61, 99.51] 
 
97.22 
(3.42) 
 
[95.52, 98.92] 
 
Post-ingestion  
 
 
 
 
 
 
 
 
 
    Go Congruent 
 
94.94 
(5.00) 
 
[92.46, 97.42] 
 
94.50 
(3.15) 
 
[92.93, 96.07] 
 
    NoGo Congruent 
 
99.83 
(.38) 
 
[99.64, 100.02] 
 
99.28 
(1.02) 
 
[98.77, 99.78] 
 
    Go Incongruent 
 
94.17 
(4.59) 
 
[91.88, 96.45] 
 
93.83 
(5.39) 
 
[91.15, 96.52] 
 
    NoGo Incongruent 
 
97.06 
(3.00) 
 
[95.56, 98.55] 
 
96.50 
(4.62) 
 
[94.20, 98.80] 
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N2 Amplitude 
 Figures 2 and 3 show the grand mean averaged waveforms at the frontal site 
Fz for modafinil and placebo conditions, respectively, peaking at approximately 
310ms post-stimulus onset. Visual inspection clearly demonstrates the effect of Trial 
Type and Congruency on the N2 component, with evidently greater N2 amplitude for 
nogo trials and trials with incongruent stimuli. No apparent distinctions between the 
modafinil and placebo condition are evident from the Figures. 
 
 
Figure 2. Grand mean waveforms for the modafinil condition at the midline frontal 
site (Fz) 
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Figure 3. Grand mean waveforms for the placebo condition at the midline frontal site 
(Fz) 
 Table 7 shows the peak N2 amplitude (µV) following each of the Flanker 
Go/Nogo trials. The main effect of Congruency was significant, F(1,17)=27.72, 
p<.001, ƞp
2
=.620, indicating that overall N2 amplitude was significantly greater in 
response to incongruent stimuli (M=-2.03, SD=2.78) relative to congruent stimuli 
(M=-.78, SD=2.88). There was also a significant main effect of Trial Type, 
F(1,17)=18.77, p<.001, ƞp
2
=.525, such that N2 amplitude was significantly greater 
following nogo trials (M=-2.12, SD=2.72) compared to go trials (M=-.69, SD=3.02). 
The Trial Type x Congruency interaction approached significance, F(1,17)=3.92, 
p=.064, ƞp
2
=.187, and Bonferroni corrected tests of simple main effects revealed 
significantly greater difference in N2 amplitude between go trials (M=-.97, SD=2.99) 
and nogo trials (M=-3.09, SD=2.87) for incongruent stimuli (p<.001, g=.71), relative 
to the difference in N2 amplitude between go trials (M=-.40, SD=3.29) and nogo 
trials (M=-1.16, SD=2.87) for congruent stimuli (p=.165, g=.24).  
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The main effect for Drug Condition was non-significant, F(1,17)=.40, 
p=.536, ƞp
2
=.023, suggesting that overall N2 amplitude did not differ between the 
modafinil (M=-1.29, SD=2.63) and placebo conditions (M=-1.52, SD=3.13). No 
significant interactions were found for Drug Condition x Trial Type, F(1,17)=.01, 
p=.923, ƞp
2
=.001, or for Drug Condition x Congruency, F(1,17)=.024, p=.879, 
ƞp
2
=.001. The three way Drug Condition x Trial Type x Congruency interaction was 
non-significant, F(1,17)=1.85, p=.192, ƞp
2
=.098.  
 
Table 7 
Means (Standard Deviations) and 95% CIs for N2 Amplitude (µV)  
  
Modafinil 
 
Placebo 
 M (SD) 95% CI M (SD) 95% CI 
 
 
     Go Congruent 
 
-.38 (3.40) 
 
[-2.08, 1.31] 
 
-.42 (3.51) 
 
[-2.16, 1.33] 
 
     NoGo Congruent 
 
-.91 (2.82) 
 
[-2.32, .49] 
 
-1.40 (3.32) 
 
[-3.05, .24] 
 
     Go Incongruent 
 
-.74 (2.86) 
 
[-2.16, .68] 
 
-1.20 (3.37) 
 
[-2.88, .48] 
 
     NoGo Incongruent 
 
-3.12 (2.71) 
 
[-4.47, -1.78] 
 
-3.05 (3.42) 
 
[-4.75, -1.35] 
 
 
Discussion 
 The aim of the present study was to investigate the effect of 200mg of 
modafinil on both behavioural and ERP correlates of inhibitory control, in a sample 
of healthy, non-sleep deprived individuals. Participants were compared on RT, 
accuracy and N2 amplitude across two experimental conditions. The hypothesis that 
the increase in RT from congruent trials to incongruent trials would be significantly 
reduced for the modafinil condition at post-ingestion testing compared to the placebo 
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condition was not supported, as indicated by the non-significant Drug Condition x 
Time x Congruency interaction. While a main effect of Congruency suggests 
participants did have slower RTs for incongruent stimuli relative to congruent 
stimuli, this did not significantly vary as an effect of Drug Condition. A trend 
towards a significant Drug Condition x Time interaction for RT was however 
observed, with significant reductions in RT from pre-ingestion to post-ingestion 
found for the modafinil and not the placebo condition. Nevertheless, this was 
observed for both congruent and incongruent trials of the task, suggesting that the 
effect was independent from inhibitory control processes. 
 The second hypothesis, that the decrease in accuracy from congruent trials to 
incongruent trials would be significantly reduced for the modafinil condition at post-
ingestion compared to the placebo condition, was also not supported. Again, this is 
evident given the non-significant Drug Condition x Time x Congruency interaction. 
A main effect of Congruency was found, indicating there were significantly less 
accurate responses to incongruent stimuli relative to congruent stimuli, though again 
this was not affected by Drug Condition.  
 A similar pattern was also observed for amplitude of the N2 component. The 
hypothesis that the combined nogo and flanker effect of the Flanker Go/Nogo task 
would result in significantly increased N2 amplitude in modafinil conditions relative 
to placebo conditions was not supported, as evidenced by the non-significant Drug 
Condition x Trial Type x Congruency interaction. While significant main effects 
were observed for Trial Type and Congruency, with a trend towards a significant 
Trial Type x Congruency interaction; there was no interaction of Drug Condition 
with either of these variables. 
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Mood, Fatigue and Alertness 
 Significant Drug Condition x Time interactions were observed on both 
Vigour-Activity and Fatigue-Inertia subscales of the POMS-SF. Interestingly, these 
interactions were not a product of significant enhancement in the modafinil 
condition, but rather the result of significantly lower ratings in the placebo condition. 
Modafinil did however appear to improve ratings on the Depression-Dejection 
subscale in comparison to placebo, though it is worth noting that ratings on the 
Depression-Dejection subscale were generally low, with scores of 0 frequently 
observed at baseline for both conditions. The lack of significant differences on any 
other subscale suggests that modafinil had little influence on subjective mood as 
measured by the POMS-SF. These findings are concordant with previous literature, 
whereby modafinil is rarely associated with negative changes in subjective mood, 
though in some cases has been found to improve mood related to alertness and 
energy (Battleday & Brem, 2015; Minzenberg & Carter, 2008; Repantis et al., 2010). 
Also consistent with past literature; reported side effects were minor and non-
distressing, and usually observed in both modafinil and placebo conditions. 
Confidence of ingesting modafinil was found to be significantly greater in the 
modafinil condition relative to placebo. Despite this, median scores for both 
conditions were still at chance (≤50%), with large variation across participants, 
suggesting effects of modafinil were mostly subtle and not readily detected. 
 The effects observed on the KSS were consistent with those found on the 
Fatigue-Inertia subscale of the POMS-SF, with a significant increase in sleepiness 
reported from pre-ingestion to post-ingestion for the placebo condition, compared to 
non-significant decreases in sleepiness for the modafinil condition. Alertness items 
on VAS measures indicate there were significant decreases in alertness from pre- to 
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post-ingestion in the placebo condition, with no significant changes to alertness for 
the modafinil condition. 
Considered together, results of the POMS-SF, KSS and VAS suggest that 
participants’ subjective wakefulness and alertness significantly decreased throughout 
the session, though that this fatigue was mitigated by modafinil. Rather than 
providing any significant enhancement of alertness or wakefulness above baseline, 
modafinil instead provided an effect of maintenance within what was evidently a 
fatigue-inducing environment for participants. These findings are consistent with the 
role of modafinil as a wake-promoting agent, and with the effects often observed in 
studies involving sleep-deprivation (Repantis et al., 2010).  
It is not clear why the present study induced fatigue to such an extent, given 
that the sample comprised healthy, well-rested individuals. It is possible that this is a 
common effect of many studies investigating effects of modafinil in healthy 
populations, as experimental sessions are often long and tedious due to accounting 
for peak plasma levels (Minzenberg & Carter, 2008). Many studies in non-sleep 
deprived populations do not examine within-session fatigue, therefore the notion that 
participants on modafinil may simply be more awake than placebo controls by the 
time testing occurs is an important confound to consider. It is also possible that, 
being an ERP study, the present study exacerbated within-session fatigue beyond 
what would normally be observed, given that participants were required to remain 
still in a dimly lit room during cognitive testing. Post-ingestion measures of the 
POMS-SF, KSS and VAS were taken at approximately 3.25 hours post-ingestion, 
directly following cognitive testing. Increased sleepiness in the placebo condition 
may have therefore been a result having completed the measures directly after 
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testing, and consequently may not have been an accurate index of fatigue and 
alertness prior to performing the tasks. 
Behavioural and ERP Correlates of Inhibitory Control 
 In relation to the behavioural hypotheses, the present results provided little 
support for effects of modafinil in the selective improvement of inhibitory control 
processes. Incongruent stimuli were associated with the slower RTs and less accurate 
responses overall, suggesting that the task was effective at eliciting a flanker effect. 
This finding was in accord with the precursory behavioural hypotheses, as well as 
previous literature advocating the use of the Flanker Go/NoGo paradigm for the 
measurement of inhibitory processes (Heil et al., 2000). However, the flanker effect 
did not significantly vary between the modafinil and placebo conditions, suggesting 
that modafinil did not enhance the extent to which participants were able to 
effectively respond to inhibitory control-related stimuli. Further, although overall 
reductions in RT were found for the modafinil condition from pre- to post-ingestion, 
this effect did not appear to be driven by an enhancement of inhibitory control, due 
to the lack of interaction with Congruency. Non-significant effects of Time or Drug 
Condition in the accuracy data do however suggest little evidence for a speed / 
accuracy trade-off for the effects on RT. 
 These findings are in contrast to those previously reported by Turner et al. 
(2003), whereby significantly reduced error rates and stop-signal RTs were observed 
in participants following modafinil administration. Rather, the present results are 
more closely aligned with the findings reported in studies by Randall et al. (2004) 
and Randall, et al. (2005b), in which modafinil only enhanced performance on 
congruent trials of the Stroop task, and not the inhibitory control-related incongruent 
trials. This interaction also reflects the behavioural findings reported by Minzenberg 
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et al. (2014), whereby significant decreases in RT for both congruent and 
incongruent trials of the POP task were found between testing blocks for the 
modafinil condition, but not the placebo condition.   
Within previous literature investigating effects of modafinil on healthy 
individuals, a number of studies have failed to detect differences on behavioural 
measures of inhibitory control, but have reported differences in neural activity 
associated with inhibitory control processes (Minzenberg et al., 2014; Minzenberg et 
al., 2008; Rasetti et al., 2010). This has been suggested to be due to the insufficient 
sensitivity of tasks to detect enhancement in healthy populations, often as a result of 
ceiling effects (Battleday & Brem, 2015). The use of electrophysiological and 
neuroimaging techniques may therefore provide additional insight regarding the true 
extent of effects, even when no differences on behavioural measures are observed.  
The electrophysiological results of the present study, however, were 
supportive of the findings of the behavioural data, with no apparent effects of 
modafinil on inhibitory control-related processes. Amplitude of the N2 component 
was shown to be significantly greater for incongruent stimuli relative to congruent 
stimuli, and for nogo trials relative to go trials, and the increase in N2 amplitude 
from go trials to nogo trials was significantly greater for incongruent stimuli relative 
to congruent stimuli, as was proposed by the original hypothesis. This increase in 
amplitude was not found to be greater for the modafinil condition relative to the 
placebo condition, suggesting that the extent of inhibitory control resources did not 
differ between the conditions. 
Considered together, the results of the present study provide little support for 
the notion that modafinil may selectively enhance inhibitory control processes. The 
overall pre- to post-ingestion reduction in RT for the modafinil condition is however 
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similar to effects previously observed in past studies (Minzenberg et al., 2014; 
Randall et al., 2004; Randall, et al., 2005b). Although it provides no evidence for the 
selective enhancement of inhibitory control, a reduction of RT may provide some 
tentative evidence for a general enhancement of processing speed following 
modafinil ingestion, possibly through the enhancement of sustained attention and 
vigilance. Past research has indicated improvements on these processes following 
modafinil administration, with greater performance observed on the RVIP task of 
sustained attention (Randall, Shneerson & File, 2005a; Randall et al., 2005b), and 
Detection of Repeated Numbers (DRN) vigilance task (Baranski, Pigeau, Dinich, & 
Jacobs, 2004). Despite this, evidence in this area remains equivocal, and is beyond 
both the aims and scope of the present study to attribute effects with any certainty. 
The present results do however provide grounds for future investigation in this area, 
and particularly research utilising ERP techniques. Investigation of early ERP 
components in relation to performance on tasks of sustained attention may provide 
more conclusive evidence regarding effects on early processing and processing 
speed. 
It is, however, worth considering the apparent confound of within-session 
fatigue when regarding effects of enhanced performance. The results of the analyses 
conducted on the POMS-SF, KSS and VAS indicated that participants in the placebo 
condition experienced significant increases in sleepiness and decreases in alertness 
throughout the session, with no apparent effect in the modafinil condition, likely due 
to the wake-promoting effects of the drug. Differences in subjective wakefulness and 
alertness between the conditions may therefore in itself have causative influence over 
differences in behavioural performance, irrespective of any selective 
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neuroenhancement to specific cognitive processes (Randall, Shneerson & File, 
2005a). 
This is a problematic notion for past research investigating effects of 
modafinil, or any proposed cognitive enhancer, given that indices of wakefulness and 
within-session fatigue are often overlooked when samples comprise healthy, non-
sleep deprived individuals (Randall, Shneerson, & File, 2005a). The study by Turner 
et al. (2003) is one few to report clear effects of behavioural enhancement on 
inhibition-related paradigms, however no ratings of sleepiness or fatigue were taken 
throughout the sessions, and therefore the extent to which this may have influenced 
the results is not evident. By contrast, in studies where wakefulness and alertness are 
monitored throughout the session, few effects of modafinil are observed when 
indices of fatigue do not vary between groups (Randall et al., 2004; Randall, et al., 
2005b). The notion that within-session fatigue may account for the inconsistencies in 
the literature is important to consider, and is a limitation of existing reviews that have 
failed to appropriately address this issue (Battleday & Brem, 2015). Again, it is 
possible that effects of fatigue in the present study were exacerbated beyond what is 
normally observed in the literature due to the nature of the present design, therefore 
future studies utilising ERP techniques should be particularly conscious of this 
potential confound.  
Methodological Limitations   
 Similar to previous studies utilising simple test paradigms of cognitive 
performance (Minzenberg & Carter, 2008; Rasetti et al., 2010); an additional 
limitation of the present study is the substantial ceiling effects observed in the 
Flanker Go/Nogo paradigm. This was particularly apparent for the accuracy data, 
whereby participants were performing near ceiling across all time points of the study, 
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irrespective of Drug Condition. Despite this, large effects of Congruency and Trial 
Type were still discernible within the data, though it could be argued that ceiling 
performance may have masked what would have been more subtle effects of 
modafinil on performance.  
In their review, Battleday and Brem (2015) argued that ceiling effects in low-
complexity tasks are a primary factor as to why inconsistencies in results are often 
observed across studies. Considering the recommendation to use novel and more 
complex tasks to assess neuroenhancement, the present study compromised; utilising 
a well validated measure of a specific cognitive process, and attempting to increase 
task difficulty through brief stimulus presentations and greater levels of visual and 
phonological interference. Although it is possible that effects of modafinil on 
inhibitory control may have been observed had the task been more difficult, it is 
worth noting that modafinil did not seem to interact with inhibitory processes within 
the reaction time data or the electrophysiological data of the N2 component, both of 
which are less susceptible to ceiling effects. This is nonetheless something to be 
explored further in future research, as effective increases in task difficulty or 
cognitive load may potentially manifest effects of modafinil not found by the present 
study.  
 Also similar to previous research (Minzenberg & Carter, 2008; Minzenberg et 
al., 2014), practice effects both within- and between-sessions represent a 
considerable limitation of the study. Irrespective of Drug Condition, significant 
decreases in RT were noted from pre- to post-ingestion, and preliminary analyses 
including order of drug administration revealed decreases from session 1 to session 
2. In these analyses, there were no interactions between order and the interactions of 
interest and therefore, order was omitted from subsequent analyses given power and 
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sample size limitations. It is possible however that these effects could be better 
investigated using a more powerful design or a Mixed Models approach to analysis. 
Despite this, effects of Drug Condition were still discernible in relation to Time, 
where although practice effects were evident in both conditions, significant 
reductions in RT were observed only following modafinil ingestion. Further, the 
electrophysiological results were still in accord with overall results of RT, though 
future research may also wish to consider collecting ERP data at baseline, as this was 
beyond the means of the present study.   
It may be argued that had the present study used a between-subjects design, 
effects of modafinil would have been more readily observable, though this is not 
necessarily true of the current literature, with mixed results observed in both parallel 
and crossover designs. Nonetheless, while it was not viable for the present study to 
use a between-subjects design due to limits on time and sampling, future studies may 
wish to consider doing so in order to avoid effects of practice on susceptible tasks.  
Summary and Conclusions 
 The present study aimed to investigate the extent to which 200mg of 
modafinil may influence behavioural and electrophysiological correlates of 
inhibitory control, within a sample of healthy, non-sleep deprived individuals. 
Expanding on previous research examining effects using only behavioural measures 
of performance, the present study utilised a temporally-precise, ERP technique as an 
additional measure of inhibitory control. In sum, the results of the present study 
validated the role of modafinil as a wakefulness and alertness promoting agent, 
though provided no evidence for its use in the selective enhancement of inhibitory 
control-related processes. Some tentative evidence is provided for the enhancement 
in processing speed via effects on vigilance, though further research is necessary to 
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clarify these effects. Important considerations are however raised regarding the effect 
of within-session fatigue in studies attempting to identify effects of 
neuroenhancement, given the long experimental sessions that are often necessary, 
and potential for induced fatigue.  
In terms of the efficacy of modafinil as a cognitive enhancing agent, the 
results of the present study provide little evidence beyond effects on processing 
speed. Equivocal evidence remains for effects on other executive functions, as well 
as processes of attention, learning and motivation (Battleday & Brem, 2015; Repantis 
et al., 2010). The extent to which these effects are observed in the absence of 
experimental fatigue is, however, a consideration requiring more attention in future 
studies and reviews.  
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Appendix A  
INFORMATION SHEET 
 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
 
Chief Investigators: Dr Raimondo Bruno & Dr Allison Matthews 
Researchers:  Caitlin Harris & Oliver De Angelis *  
*This research is being conducted as part of an Honours degree in the School of 
Psychology, UTAS. 
 
We would like to invite you to participate in a study aiming to better understand the 
way that the prescription drug Modafinil effects cognitive processes such as attention 
and associated brain activity. The use of this drug is increasing Australia wide, and 
we are interested in better understanding its effects. There have been a number of 
studies which have shown some effects of stimulant drugs on cognitive processes but 
very few studies have examined Modafinil. Getting a better understanding about 
Modafinil is particularly important, not just to understand how the drug affects 
cognition, but also to be able to provide information for doctors to give to potential 
users of the drug. 
 
Why have I been invited to participate in this research? 
You are invited to take part in the study if you are male and aged 18-30 years old. In 
order for the results of the study to be clear, all participants need to speak English 
fluently, and have had no previous neurological or mental health problems. In 
addition, participants must NOT use illicit drugs, smoke cigarettes daily, consume 
alcohol at harmful levels or be female. 
 
What will my participation involve? 
Participating in this study is unlikely to cause any discomfort or distress. Firstly, if 
you are interested in taking part in the study, you will be invited to complete a series 
of confidential screening questionnaires. These will enquire about what your mood 
has been like recently. This will include a psychological distress scale, schizotypal 
personality questionnaire, a psychosis screener and some questions regarding your 
alcohol, caffeine and drug use. All data collected will be kept in the strictest 
confidence, and the way we maintain this is described below. This screening process 
is simply to ensure that participants in the study are not taking medications or 
experiencing other issues that may cause a negative response to Modafinil.   
 
During the study, we will ask for some basic information about yourself (such as age, 
sex, years of schooling). During each testing session, you will be fitted with an 
electrode cap for measuring your brain activity. You will be asked to complete some 
computer-based tasks which relate to cognitive processes such as attention. In these 
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tasks you will respond with a button press when particular stimuli appear on the 
screen. Previous studies using the same dose of Modafinil have found side effects for 
some participants, including dry mouth, mild headaches and mild nausea. There will 
be two testing sessions which will occur at the University of Tasmania, and will take 
around four hours each. You will be reimbursed up to $80 for your time and out-of-
pocket expenses. 
 
Before taking part in the study you must organise for a reliable friend or family 
member to collect you from the lab at the end of the testing session, in case you are 
still experiencing any effects following the possible administration of Modafinil. The 
researcher will check that this has been organised before the testing session begins. 
When the nominated person collects you, they will be given a copy of the medication 
information sheet about Modafinil, and the main points will be verbally explained. 
Namely, it will be explained that they should ensure you do not drive a vehicle or 
operate machinery for the rest of the day, and do not consume alcohol. In the 
unlikely event that you do experience unpleasant side effects while completing the 
testing, the researchers are trained in first aid, and the chief investigators will be 
available on site to provide further assistance if required. Additionally, the researcher 
will explain that in the unlikely event of you experiencing an adverse reaction once 
you have left the premises, you should contact your doctor or be taken to hospital 
immediately. 
 
There are no specific risks associated with the measurement of brain activity. 
However, if you have sensitive skin there is a small possibility of a slight skin 
reaction from electrode preparation materials. If you believe there is a chance that 
your skin may react you are advised to reconsider participation. 
 
How private is the information that I give? 
It is important for you to know that all data collected will be kept in the strictest 
confidence. All data will be identified by a coding system and no names or contact 
numbers will appear on any records. In this way, your identity is protected, and there 
will be no risk of legal or social problems arising from your participating in the 
study. All information gathered in the study will be reported as grouped data, and 
because no personal information is recorded, no individual participants will be 
identifiable in the research output. Data from the study will be stored securely for 
five years in locked cabinets in the School of Psychology, as is legally required, and 
then destroyed by shredding. 
 
Can I withdraw from the research if I wish? 
Participation in this study is entirely voluntary. You may, at any time, decline to 
answer any question you so wish, or withdraw from the study without effect or 
explanation. 
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You will be given a copy of this information sheet to keep. Please retain this 
information sheet in case you decide at a later data that you would like to retract your 
data from the study.  
 
Who do I need to contact if I have any questions about the research? 
If you would like more information about the research, please contact Dr Allison 
Matthews on 62267236 (or email Allison.Matthews@utas.edu.au) or Dr Raimondo 
Bruno 6226 2190 (Raimondo.Bruno@utas.edu.au). If you would like to find out 
about the results of the study, these will be available from Dr Matthews after 
November 2016. 
 
Has this research been approved by an ethics committee? 
This project has been approved by the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature, or 
complaints about the manner in which the study is conducted, you may contact the 
Executive Officer of the Human Research Ethics Committee (Tasmania) Network on 
(03) 6226 7479 or human.ethics@utas.edu.au. Please quote the ethics reference 
number H0011386. 
Who can I contact if I have any concerns? 
If you have any personal concerns related to the study, you may choose to discuss 
these concerns confidentially with a counsellor at the University Psychology Clinic 
free of charge. Confidential appointments may be made on (03) 6226 2805. 
 
Thank you for your interest in the study and for taking the time to read this 
information sheet. We hope you will be interested in participating in this study. 
 
Raimondo Bruno & Allison Matthews Oliver De Angelis/Caitlin Harris 
Chief Investigators                      Student Researchers   
(03) 6226 2190 or (03) 6226 7236 
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CONSENT FORM 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
  
1. I have read and understood the 'Information Sheet' for this study. 
2.  I have read and understood the ‘Consumer Medicine Information’ regarding 
modafinil. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves: 
 Attending two testing sessions of approximately four hours duration 
 Completing a series of cognitive tasks while my brain activity is 
measured 
5. I understand that all research data will be securely stored on the University of 
Tasmania premises for five years, and will then be destroyed. 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered from me for the study may be published 
provided that I cannot be identified as a participant. 
 
8. I understand that the researchers will maintain my identity confidential and that 
any information I supply to the researcher(s) will be used only for the purposes 
of the research. 
 
9. I agree to participate in this investigation and understand that I may withdraw 
at any time without any effect, and if I so wish, may request that any data I 
have supplied to date be withdrawn from the research. 
 
10. This project has been approved by the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature, or 
complaints about the manner in which the study is conducted, you may contact 
the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network on (03) 6226 7479 or human.ethics@utas.edu.au. Please quote the 
ethics reference number H0011386. 
  
Name of Participant: 
Signature: Date: 
 
Statement by Investigator  
 I have explained the project & the implications of participation in it to 
this volunteer and I believe that the consent is informed and that he/she 
understands the implications of participation  
 
Name of investigator   
   
Signature of     investigator Date 
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Appendix B 
Ethics Approval Letter 
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Appendix C 
Experimental session questionnaire 
Date ____/____/____       Participant ID 
_________ 
 
1. Check that participant has abstained from alcohol for 24 hours and illicit drug use 
since completing the screening questionnaire 
2. Weight ___________ kg 
Height____________ cm 
BMI _____________ 
 
3.  Have you consumed any medications in the past week (or any prescribed 
medications since completing the screening questionnaire)? 
If yes, please detail:  
 
3. How many cups of coffee (or any other caffeinated drinks/products) have you 
consumed today? _____  
If > 0. How many hours since your last caffeinated drink ______ hours 
4. Have you had any tobacco or nicotine products today? Yes / No  
If yes, how many cigarettes (or nicotine products) have you had today? ____ 
If yes, How many hours since your last cigarette (nicotine product) ______ hours 
5.  What have you had to eat today? How long since you last ate something? 
_________ mins 
6. Approximately how many hours sleep did you have last night? ____ 
 
 
 
 
 
 
 
Medication Number of 
occasions 
Time since last used Estimated dose 
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Experimental session questionnaire (extended) 
 
Date ____/____/____      Participant ID 
_____________ 
 
1.        What grade of school did you complete (up to year 12/secondary school)? 
            Year_______ 
 
2.        Have you completed any courses after school? 
            No…………………………….…0 
            Yes, trade/technical…...1 
            Yes, university………….…2 
            Specify qualifications___________________________ 
 
3.        Are you currently studying? 
            No…………………………………0 
            Yes, trade/technical……….1 
            Yes, university……….…….. 2 
            Specify ___________________________ 
 
4.  How are you currently employed? Mark ONE response 
 Not employed ………..………….…1 
 Full time ………..……………………..2 
 Part time/casual ………..…………3 
 Full time student ………..…………4 
 Home duties ………..……………….5 
 Work and study …………………… 6 
 Part-time student ………..………..8 
 Other ………..…………………………..9 
 Specify________________________________ 
 
 
 
 
 
  
60 
 
 
Appendix D 
Side Effect Checklist 
During this experimental session have you experienced any of the following 
symptoms? 
Yes      No  
        headache 
        nausea 
        dry mouth 
        runny nose 
        sore throat 
        nervous feeling 
        dizziness 
  
 
Are you currently experiencing any other adverse symptoms? Please specify. 
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Appendix E 
 
Visual Analogue Scales of Subjective Performance 
 
Participant number:        
 Test point:  
 
Please mark on each line at the point which most accurately reflects your 
level of agreement AT THE MOMENT with the below statement: 
 
1. I feel alert 
STRONGLY  
AGREE 
 STRONGLY  
DISAGREE 
 
2. I feel that I will be able to perform the attention tasks to the best of my ability 
STRONGLY 
 AGREE 
 STRONGLY  
DISAGREE 
 
3.I do not feel that my driving would be impaired right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
 
4.I feel capable of driving safely right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
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Visual Analogue Scales of Subjective Drug Effects 
 
Participant number:        
 Test point:   
 
Please mark on each line at the point which most accurately reflects your 
level of agreement AT THE MOMENT with the below statement: 
 
1. Strength of drug effect 
NO EFFECT 
 
 VERY 
STRONG 
EFFECT 
2. Liking of the drug effect 
DISLIKE VERY 
MUCH 
 
 LIKE VERY 
MUCH 
3. Alert level 
NOT ALERT 
 
 VERY ALERT 
4. Intoxication 
NOT 
INTOXICATED 
 
 VERY 
INTOXICATED 
 
